Sushmita Roy is a Professor at the University of Wisconsin–Madison, affiliated with the Department of Computer Sciences and the College of Letters and Science. Her research focuses on developing computational methods in statistical machine learning to understand gene regulatory networks in living cells, particularly under environmental, developmental, disease, and evolutionary contexts. She explores bulk and single-cell genomic data integration to study processes like cell fate specification, host-microbe interactions, and diseases such as cancer and neurodevelopmental disorders. Her work emphasizes three key areas: inference of genome-scale transcriptional networks, evolutionary analysis of regulatory networks, and 3D genome organization dynamics. Roy’s lab collaborates across disciplines, leveraging genomic data from plant and mammalian systems. She has contributed to methodologies for analyzing chromatin accessibility, single-cell profiling, and network-based models of pathogen systems. Her affiliations include Wisconsin Institutes for Discovery, and she is a leader in computational biology and systems genomics research.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Knut Drescher is an Associate Professor at the Biozentrum, University of Basel , leading a research group focused on bacterial biofilms , swarming , and microbial multicellularity . Previously, he served as a Professor of Biophysics and Max Planck Research Group Leader at Philipps-Universität Marburg (2015-2021) and conducted postdoctoral research at Princeton University. Research Interests: Physical and biological mechanisms of biofilm formation Cell-cell interactions in microbial communities Antibiotic resistance in biofilms Hydrodynamics of bacterial swarms Evolution of cooperation in multispecies biofilms Development of bioimaging software (BiofilmQ, BacStalk) Scientific Awards: 2023: SNSF Consolidator Grant 2019: Heinz Maier-Leibnitz Prize (DFG), VAAM Research Prize, IUPAP Young Scientist Prize 2016: ERC Starting Grant Advising & Grants: Advises PhD and Master's students in microbiology, biophysics, and bioinformatics Secured major grants from ERC , HFSP , and DFG
Michael Groll serves as Professor and Chair of Biochemistry at the Technical University of Munich (TUM), where he leads structural biology and enzymology research with a focus on proteasome mechanisms and inhibitor development. His laboratory, located at the Ernst-Otto-Fischer-Str. 8 campus in Garching, maintains active collaborations in drug discovery for cancer and infectious diseases. His primary research domains include proteasome inhibition, enzyme catalysis, and natural product biosynthesis, employing X-ray crystallography, biochemical assays, and bioengineering to dissect molecular mechanisms. Recent work emphasizes AI-guided enzyme optimization, bacterial stress response targeting, and structural characterization of halogenation enzymes, reflecting interdisciplinary approaches bridging chemistry and biology. Analysis of his 2023-2025 publications reveals consistent innovation in proteasome-targeted therapeutics, with 15 high-impact papers featuring structural insights into enzyme-inhibitor complexes and biosynthetic pathways. Key trends include engineering megasynthetases for immunoproteasome inhibitors, optical control of protein degradation, and elucidating metal-dependent mechanisms in antibiotic biosynthesis. No scientific awards were documented in the provided source material. While specific grant details and student mentorship records were not disclosed, his extensive publication record indicates leadership in collaborative research projects involving structural biology and chemical biology methodologies. The Chair of Biochemistry under Prof. Groll operates as a hub for structural enzymology, housing facilities for protein crystallography, enzyme kinetics, and natural product characterization. His team actively contributes to TUM's research ecosystem through partnerships with pharmaceutical groups and international structural biology consortia.
Trent K. Bollinger is a Professor in the Department of Veterinary Pathology at the University of Saskatchewan's Western College of Veterinary Medicine (WCVM), and serves as Regional Director for the Western/Northern Region of the Canadian Wildlife Health Cooperative (CWHC). His academic credentials include a BSc (Honours) from the University of Saskatchewan (1984), a DVM (Distinction) from the University of Saskatchewan (1988), and a DVSc in Pathology from the Ontario Veterinary College (1992). Dr. Bollinger's research focuses on the pathology and epidemiology of diseases in wildlife and fish, with particular emphasis on chronic wasting disease in deer/elk and white-nose syndrome in bats. He has conducted extensive studies on disease transmission dynamics, wildlife population health, and the ecological impacts of emerging pathogens. His work bridges veterinary science, ecology, and conservation biology. His publications demonstrate expertise in viral and bacterial zoonoses, fungal pathogens affecting bats, and spatial epidemiology of wildlife diseases. Recent research highlights include investigating sylvatic plague in prairie dogs, coronavirus persistence in hibernating bats, and landscape connectivity's role in chronic wasting disease spread. His studies often combine molecular diagnostics, field observations, and ecological modeling. Dr. Bollinger collaborates with national and international wildlife agencies, contributing to disease surveillance and management strategies for endangered species. His work emphasizes the interconnectedness of wildlife health, ecosystem health, and public health concerns.
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Uwe Himmelreich is a Full Professor at the Faculty of Medicine, KU Leuven , leading the Biomedical MRI unit. He is actively involved in the Medical Imaging Division , KU Leuven Brain Institute , KU Leuven Institute for Integration of Micro- and Nano-scale Technologies , and KU Leuven Cancer Institute . Role: Full Professor and Head of Biomedical MRI Affiliations: Faculty of Medicine, Medical Imaging Division, LBI, LIMNI, LKI His research spans neuroscience , cardiovascular imaging , and nano/micro-scale technologies . Key projects include: MindMAP: Radiotherapy-induced neurotoxicity in juvenile brains Preclinical cancer models for oral tumors Quantitative T2 mapping of lung disease in murine models Neuroinflammation and cognitive decline in cryptococcosis Resistance training effects on cortical thickness in aging cohorts His work integrates MRI , multi-photon microscopy , and novel contrast agents for longitudinal in vivo studies. Methodologies include vascular density mapping , proton therapy verification , and preclinical radiotherapy evaluation . Notable contributions include: 2025: JAK/STAT inhibition in malaria-induced inflammation 2025: Manganese-enhanced MRI for cardiac injury 2025: Quantitative lung imaging at 9.4T 2024: IVIM as vascular density marker in rat brain 2024: Phase-change ultrasound agents for proton therapy
Sharon Rozovsky is a Professor in the Department of Chemistry and Biochemistry at the University of Delaware's College of Arts & Sciences, where she leads research on oxidative stress response mechanisms and protein quality control pathways. Her work bridges biochemistry, chemical biology, and structural biology with direct implications for understanding neurodegenerative diseases and viral pathogenesis. Her academic foundation includes a B.S. from Tel Aviv University (1994) and a Ph.D. from Columbia University (2000), establishing her expertise in protein dynamics and redox biochemistry. These credentials underpin her innovative approaches to studying cellular stress responses. Rozovsky's research program centers on selenoproteins—proteins containing the rare amino acid selenocysteine—and their critical roles in endoplasmic reticulum (ER) stress resolution. She investigates how membrane-bound selenoproteins like Selenoprotein S and K regulate the ER-associated degradation (ERAD) pathway, with recent work revealing their surprising autoproteolytic activity and involvement in SARS-CoV-2 replication. Her lab pioneers chemical tools including expressed protein ligation and advanced 77Se NMR spectroscopy to characterize these systems at molecular resolution. Analysis of her 2021-2025 publications shows dominant themes in selenoprotein structure-function relationships, ER stress mechanisms, and viral interactions, alongside methodological innovations in cryo-EM grid technology and NMR. This body of work demonstrates consistent focus on redox biochemistry with expanding applications in virology and structural biology. No major scientific awards or fellowships were explicitly documented in the available materials, though her research impact is evident through high-impact publications and methodological contributions. She directs the active Rozovsky Research Group, mentoring graduate students and postdoctoral researchers in biochemical and biophysical techniques. Her laboratory operations are supported by competitive funding including an NSF CAREER award (2011) focused on selenoprotein reactivity, reflecting sustained recognition of her innovative research program.
Dr. Anton Lavrinienko is a Lecturer at the Department of Health Sciences and Technology at ETH Zürich, affiliated with the Biotechnology of Food Systems group. His research focuses on microbiome studies, environmental health, and the impact of pollution and radiation on ecosystems and microbiota. He is based in Zurich, Switzerland, and teaches the course Applied Bioinformatics: Microbiomes (Autumn Semester 2025). His work integrates molecular biology, ecology, and public health to address challenges in food systems and environmental sustainability. Research interests include microbial diversity in polluted environments, radiation effects on wildlife, and the application of genomics to biodiversity conservation. He collaborates on projects such as the European Reference Genome Atlas and studies microbial responses to anthropogenic contamination in urban and natural ecosystems. Dr. Lavrinienko’s studies often involve fieldwork in regions like Chernobyl, investigating how chronic radiation and metal pollution alter microbiota and organismal health. His findings contribute to understanding ecological resilience and human health implications of environmental stressors. He emphasizes open data standards and FAIR principles in microbiome research.
Associate Professor Colin Jackson is affiliated with the Research School of Chemistry at the Australian National University College of Physical & Mathematical Sciences . His research spans enzyme engineering, synthetic biology, and protein evolution, with a focus on directed evolution approaches for biocatalysis and molecular biophysics. Former CSIRO and Weizmann Institute researcher Key projects: plastic degradation enzymes, viral protease inhibitors, noncanonical amino acid incorporation His work leverages ancestral sequence reconstruction and machine learning to explore protein sequence spaces, with notable outputs in fitness landscape analysis and biocatalytic applications . Recent publications highlight advancements in: Plastic biodegradation enzyme engineering Antiviral peptide design targeting SARS-CoV-2 Fluorinated noncanonical amino acids for protein studies Marine bacterial transport proteins Organophosphate resistance mechanisms While no formal awards are listed in this data, his research portfolio demonstrates strong industry and biomedical applications through: ANU Researcher Portal publications Collaborative projects with international institutions 50+ funded projects including gene therapy platforms and food waste solutions
Albert M. Berghuis is a Professor in the Department of Biochemistry at McGill University's Faculty of Medicine. His research focuses on structural mechanisms of antibiotic resistance and fungal pathogenesis using advanced techniques including X-ray crystallography, electron microscopy, and computational chemistry. His primary research interests include: Structural basis of antibiotic resistance mechanisms, particularly against aminoglycosides Development of novel antimicrobials through structure-based drug design Structural studies of fungal-specific metabolic pathways for antifungal drug discovery Enzyme mechanisms involving protein-small molecule interactions Analysis of his recent publications reveals a consistent focus on structural elucidation of resistance mechanisms, with particular emphasis on aminoglycoside-modifying enzymes and fungal targets. His work bridges structural biology with therapeutic development, showing strong translational potential in combating antimicrobial resistance. Professor Berghuis maintains the Berghuis Lab with facilities in both the McIntyre Medical Sciences Building and the Francesco Bellini Life Sciences Building. His laboratory employs integrated structural biology approaches to tackle pressing problems in infectious disease treatment.
Susan Butler-Wu, PhD, D(ABMM), SM (ASCP) serves as the Director of Medical Microbiology at LAC+USC Medical Center and holds the position of Clinical Associate Professor of Clinical Pathology at the Keck School of Medicine of the University of Southern California. She received her PhD in Molecular Microbiology from Tufts University and completed postdoctoral fellowships in Tuberculosis Pathogenesis at New York University and Medical and Public Health Microbiology at the University of Washington. Prior to her current role, she was the Associate Director of Clinical Microbiology at the University of Washington Medical Center. Research Focus: Rapid diagnostics for infectious diseases, antimicrobial resistance detection, and diagnostic stewardship. Professional Roles: Member of the editorial board of the Journal of Clinical Microbiology; serves on working groups for the Clinical Laboratory Standards Institute (CLSI) and the American Society for Microbiology (ASM). Key Contributions: Extensive publications on MALDI-TOF mass spectrometry, SARS-CoV-2 diagnostics, and antimicrobial resistance trends.
Dr. Arpan Mehta is an Independent Investigator at the MRC Protein Phosphorylation and Ubiquitylation Unit, specializing in neurodegenerative diseases with a focus on Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia. He was awarded the 51st Sir John Halliday Croom Medal and Lectureship by the Royal College of Physicians of Edinburgh for his groundbreaking research on ALS mechanisms. His work explores the role of kinases and genetic mutations (e.g., C9ORF72) in neurodegeneration, alongside mitochondrial dysfunction and clinical trial methodologies. Research interests include molecular mechanisms underlying ALS, neuroimmunology, and improving clinical trial designs for neurodegenerative diseases. Dr. Mehta advocates for rigorous research standards, addressing reproducibility challenges, and optimizing therapeutic approaches. His recent studies investigate mitochondrial bioenergetic deficits in ALS motor neurons and the impact of cerebrospinal fluid (CSF) toxicity. Awards: Sir John Halliday Croom Medal and Lectureship (2025) His publications span clinical neurology, neurodegenerative disease mechanisms, and ethical aspects of medical practice. Dr. Mehta emphasizes interdisciplinary collaboration to advance understanding of ALS pathogenesis and translational therapies.
Yan Liu is a Senior Lecturer in Glycosciences at Imperial College's Department of Metabolism, Digestion and Reproduction (Faculty of Medicine). She leads the Wellcome Trust-funded Carbohydrate Microarray Facility and co-leads the GlycoTWINNG Network. Her research focuses on glycan-mediated interactions in host-microbiota interfaces, with applications in infectious diseases and reproductive health. She holds a B.Sc. from Peking University and a Ph.D. from the University of Bristol, followed by postdoctoral work at Imperial College under Professor Ten Feizi FRS. Her academic journey includes roles as a Microarray Project Leader and co-investigator in the March of Dimes European Preterm Birth Research Centre. She is PI of a £1.34M Wellcome Trust grant maintaining Imperial's Carbohydrate Microarray Facility, advancing glycan array technologies. Research interests span microbiology, immunology, and biomolecular chemistry, with a focus on glycobiology. Key contributions include defining glycan interactions in pathogen-host systems (e.g., Candida albicans, adenoviruses), developing glycan probes, and analyzing vaginal microbiota impacts on preterm birth. Grants and collaborations include EPSRC Translational funding and the UK 'FluTrialMAP' consortium. Labs affiliations include the Glycosciences Laboratory and Imperial's Institute of Infection.
Professor Tariq Butt of Swansea University's Faculty of Science and Engineering leads the Biocontrol and Natural Products (BANP) group , focusing on entomopathogenic fungi and natural product-based biopesticides for managing pests impacting food security , human health , and agriculture . He co-directs the Natural Products BioHub and Health Technology Solutions Research Institute . His cross-disciplinary research includes collaborations with Dr Joel Loveridge (Chemistry) for chemical ecology, Professor Chedly Tizoui (Engineering) for plant-based molluscicides, and Professor Dan Eastwood (Biosciences) for fungal biocontrol. Externally, he works with experts in Greece, Brazil, Turkey, Saudi Arabia , and companies like Certis Belchim and Lallemand . Recent publications highlight his work on fungal volatile organic compounds for pest control, mosquito repellents , and microbial consortia to reduce chemical dependencies. He has supervised over 35 PhD/MSc students and contributed to 174+ peer-reviewed articles and 14 book chapters .
